← All Sponsors

SPONSOR

Zhejiang Yangli Pharmaceutical Technology Co., Ltd.

Total Trials

1

Recruiting

1

Phases

Phase 1, Phase 2

Conditions studied: Cancer Neoplasms Neoplasms, Breast Tumor PARP Ovarian Neoplasms Prostatic Cancer Pancreatic Cancer Breast Cancer Biliary Cancer

NCT06819215 Phase 1, Phase 2

Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors